EducationPhD University of Chicago, 2004 (Health Economics, Public Policy)
MS University of North Carolina (Chapel Hill), 1999 (Biostatistics)
MS University of Toledo, 1997 (Pharmaceutical Sciences)
BS Jadavpur University, 1995 (Pharmaceutical Sciences)
Contact Infoemail: firstname.lastname@example.org
web site: http://faculty.washington.edu/basua/
office: H-375Q, Health Sciences Building
Magnuson Health Sciences Center
1959 NE Pacific St.
Seattle, WA 98195-7630
campus box: 357630
Anirban Basu's work sits at the intersection of microeconomics, statistics, and health policy. His research focuses on comparative and cost effectiveness analyses, causal inference methods, program evaluation, and outcomes research.
Currently the Stergachis Family Endowed Professor and Director of the Pharmaceutical Outcomes Research and Policy Program at the University of Washington, Basu also serves as faculty member in the Department of Health Services and as an adjunct in the Department of Economics. Previously, Basu taught on the faculty of the University of Chicago Department of Medicine, where he remains an external affiliate of the Center for Health and the Social Sciences.
In addition to his position as a faculty research fellow at the National Bureau of Economic Research, Basu is as an associate editor for Health Economics, Journal of Health Economics, and Observational Studies, and has served as panelist or speaker at many economics and health studies conferences, nationally and abroad.
- HSERV 525
Advanced Health Services Research Methods III - Causal Inference Using Observational Data
Basu A, Dalal A, Canonica GW, Forshag M, Yancey SW, Nagar S, Bell CF. Economic analysis of the Phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype. Expert Rev Pharmacoecon Outcomes Res. 2017 Mar 2. doi: 10.1080/14737167.2017.1298444. [Epub ahead of print] PMID: 28277854
Dhanda DS, Guzauskas GF, Carlson JJ, Basu A, Veenstra DL. Are evidence standards different for genomic- vs. clinical-based precision medicine? - A quantitative analysis of individualized warfarin therapy. Clin Pharmacol Ther. 2017 Feb 10. doi: 10.1002/cpt.663. [Epub ahead of print] PMID: 28187492
Yeung K, Basu A, Hansen RN, Watkins JB, Sullivan SD. Impact of a Value-based Formulary on Medication Utilization, Health Services Utilization, and Expenditures. Med Care. 2017 Feb;55(2):191-198. doi: 10.1097/MLR.0000000000000630. PMID: 27579915
Basu A, Sullivan SD. Toward a Hedonic Value Framework in Health Care. Value Health. 2017 Feb;20(2):261-265. doi: 10.1016/j.jval.2016.11.022. PMID: 28237206
PI: Basu Dates: 6/1/2016 - 5/30/2017
PI: Basu Dates: 9/1/2015 - 8/31/2016
PI: Veenstra Dates: 7/1/2015 - 6/30/2016
PI: Coe Dates: 7/1/2015 - 6/30/2019
PI: Basu Dates: 6/1/2015 - 5/31/2016
PI: Flum Dates: 5/1/2015 - 4/30/2019
PI: Basu Dates: 9/1/2014 - 8/31/2015
PI: Veenstra Dates: 7/1/2014 - 6/30/2015
PI: Zatzick Dates: 7/1/2014 - 6/30/2019
PI: Basu Dates: 6/1/2014 - 5/31/2015
PI: Veenstra Dates: 10/1/2013 - 9/30/2018
PI: Basu Dates: 9/1/2013 - 8/31/2014
PI: Carlson Dates: 6/1/2013 - 11/30/2015
PI: Basu Dates: 12/28/2011 - 8/31/2016
PI: Kessler Dates: 7/1/2011 - 6/30/2015
Comparative effectiveness research is a growing field that aims to generate evidence to improve health care decisions for patients and providers. It examines the benefits and risks of different medical or healthcare interventions, including drugs and medical technology. The results of these comparison studies are used by medical professionals to make better informed healthcare decisions and thereby improve patient care.
- Anirban Basu on panel that updated guide to caregiversâ€™ decisions
- UW Professors Named American Statistical Association Fellows
- Study Examines Outcomes, Costs after Return Visits to ER
- Outcomes from patient hospitalization after return visits to ER
- Drug projected at $1 million has spark mulling installment plan (Bloomberg Business, 08/06/2015)